Soluble polypeptides and methods of use thereof for inhibiting leukemia inhibitory factor activity - Patents.com

Soluble LIFR and gp130 polypeptides with increased binding affinity provide effective inhibition of LIF activity, addressing the limitations of existing methods by reducing tumor growth and metastasis in pancreatic cancer through enhanced receptor decoy mechanisms.

JP7580800B2Active Publication Date: 2024-11-12THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021502769
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-07-20
Filing Date
2019-07-19
Publication Date
2024-11-12
Estimated Expiration
2039-07-19

AI Technical Summary

Technical Problem

Current methods for inhibiting leukemia inhibitory factor (LIF) activity, particularly in pancreatic cancer, are inadequate due to the high affinity of LIF with its receptor and the limited effectiveness of anti-LIF antibodies in competing for receptor binding.

Method used

Development of soluble leukemia inhibitory factor receptor (LIFR) and glycoprotein 130 (gp130) polypeptides with enhanced binding affinity for LIF, including fusion proteins and dimers, to effectively inhibit LIF activity and signaling.

Benefits of technology

The enhanced binding affinity of these polypeptides leads to improved inhibition of LIF activity, reducing tumor growth, metastasis, and invasion in cancer cells, particularly pancreatic cancer, by acting as decoy receptors that sequester LIF and blocking downstream signaling pathways.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580800000007
    Figure 0007580800000007
  • Figure 0007580800000008
    Figure 0007580800000008
  • Figure 0007580800000009
    Figure 0007580800000009
Patent Text Reader

Abstract

Soluble leukemia inhibitory factor receptor (LIFR) polypeptides, soluble glycoprotein 130 (gp130) polypeptides, and soluble fusion proteins and dimers comprising such polypeptides are provided. The soluble polypeptides bind to leukemia inhibitory factor (LIF). In certain embodiments, the soluble polypeptides exhibit increased binding affinity for LIF compared to the corresponding wild-type polypeptide. Nucleic acids encoding such soluble polypeptides, expression vectors comprising such nucleic acids, and cells comprising such nucleic acids and / or expression vectors are also provided. Methods of using the soluble polypeptides are also provided, including methods of inhibiting LIF activity in individuals in need thereof (e.g., to treat cancer). [Selected Figure] Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 701,399, filed July 20, 2018, which is incorporated herein by reference in its entirety. [Background technology]

[0002] Leukemia inhibitory factor (LIF) is a multifunctional cytokine that belongs to the IL-6 superfamily. Other members of the IL-6 superfamily include oncostatin M (OSM), IL-6, IL-11, ciliary neurotrophic factor (CNTF), and cardiotrophin-1 (CT-1). The LIF gene is highly conserved between humans and mice (about 75%). The LIF protein is a monomeric protein that is often modified by glycosylation. The molecular weight of the unglycosylated LIF protein is 20-25 kDa, whereas the molecular weight of the glycosylated protein ranges from 37-63 kDa.

[0003] LIF functions in both an autocrine and paracrine manner: it binds to its specific receptor (leukemia inhibitory factor receptor-LIFR) and then recruits glycoprotein 130 (gp130) to form a high-affinity receptor complex that induces activation of downstream signaling pathways, including the JAK / STAT3 signaling pathway (Figure 1).

[0004] LIF plays a role in tumor development and progression. In contrast to its role in inhibiting the growth of white blood cells, LIF often promotes the development and progression of many types of solid tumors. Overexpression of LIF promotes the proliferation of cultured human cancer cells and increases the growth of xenograft tumors formed by various human tumor cells. In addition, LIF enhances the migration and invasiveness of tumor cells and promotes metastasis of breast cancer and rhabdomyosarcoma. Hypoxia plays an important role in the overexpression of LIF in solid tumors. Cytokines such as IL-6 and IL-1β can also induce LIF expression.

[0005] In addition, LIF is a factor that is beginning to receive attention in pancreatic cancer. Recent studies show that inhibition of LIF in pancreatic cancer models, either by genetic manipulation or via antibody inhibition, improves mouse lifespan, reduces tumor burden, and limits carcinogenesis initiation. Despite being one of the most deadly cancers, treatment options for pancreatic cancer are lacking. Current methods to inhibit LIF employ anti-LIF antibodies. However, antibodies can only target one specific face of LIF and therefore cannot fully compete with receptor binding. Furthermore, the affinity of the endogenous interaction between LIF and its receptor is very high (approximately 50-100 pM), a level of affinity that is difficult to truly compete using antibodies alone. Thus, improved methods to target LIF and inhibit LIF activity / signaling are needed. Summary of the Invention

[0006] Soluble leukemia inhibitory factor receptor (LIFR) polypeptides, soluble glycoprotein 130 (gp130) polypeptides, and soluble fusion proteins and dimers comprising such polypeptides are provided. The soluble polypeptides bind to leukemia inhibitory factor (LIF). In certain embodiments, the soluble polypeptides show increased binding affinity to LIF compared to the corresponding wild-type polypeptide. Nucleic acids encoding such soluble polypeptides, expression vectors comprising such nucleic acids, and cells comprising such nucleic acids and / or expression vectors are also provided. Methods of using the soluble polypeptides are also provided, including methods of inhibiting LIF activity in individuals in need of inhibition of LIF activity (e.g., to treat cancer). [Brief description of the drawings]

[0007] [Figure 1] Schematic diagram of LIF signaling through LIFR and gp130. [Diagram 2] FIG. 1 is a schematic diagram of inhibition of LIF activity using a dimer of a soluble polypeptide according to one embodiment of the present disclosure. [Diagram 3] Panel A: Consensus mutations observed in LIFR Ig-like domain variants isolated from multiple sorts. Panel B: Binding scores of LIFR variants calculated from normalized total fluorescence binding values ​​at low (10 pM, 100 pM) LIF concentrations. All scores were normalized for differential expression on the yeast surface relative to wild type. [Figure 4] Panel A: Summary of LIFR variants generated using site-directed mutagenesis. Panel B: Binding scores of LIFR variants. Expression normalized to wild type (WT) is also shown. [Diagram 5] Consensus mutations from panel A of Figure 4 shown in the PyMOL modeled structure of human LIF (pink) bound to human LIFR (blue). Mutations are shown in red and are introduced using PyMOL. Clusters of mutations in loops 1, 2 and 3 are expanded in the inset. [Figure 6]Panel A: Consensus mutations observed in gp130 CBM domain variants isolated from multiple sortings. Panel B: Summary of mutant gp130 variants generated using site-directed mutagenesis. Panel C: Binding scores of gp130 variants. Expression normalized to wild type (WT) is also shown. [Figure 7] Consensus mutations in the gp130 ELDME structure. A selection of consensus mutations from panel A of FIG. 6 shown in the solved structure of human LIF (blue) bound to human gp130 (pink). Mutations inserted using PyMOL are shown in cyan. Clusters of mutations in zones 1 and 2 are enlarged in the inset. [Figure 8] Binding of yeast-displayed LIFR VPRVVAID and gp130 ELDME to human LIF. Panel A: LIFR wild type (WT) (circles), "PDD" variant (L218P-N42D-N277D) (squares), and VPRVVAID variant (mutations in panel A of Figure 4) (triangles) bind to human LIF. The KD of the VPRVVAID variant is measured at 30 pM, which is a 32-fold higher affinity compared to wild type (WT). Panel B: gp130 wild type (WT) (circles), "8M" variant (E4K-K5R-N14D-K45E-F46L-K83R-Y95D-N100S) (squares), and ELDME variant (mutations in panel A of Figure 4) (triangles) bind to human LIF. The KD of the ELDME variant was measured at 5 nM, which is a 12-fold higher affinity compared to the wild type (WT). [Figure 9]Schematic diagrams of examples of homodimeric and heterodimeric soluble LIFR and / or gp130 fusion constructs of the present disclosure (Panels C-F). Panel A: anti-LIF monoclonal antibody "G1" targeting the gp130 binding surface. Panel B: anti-LIF monoclonal antibody "L1" targeting the LIFR binding surface. Panel C: gp130 CBM domain (ELDME) Fc fusion. Panel D: LIFR CBMI-Ig-like CBMII domain (VPRVVAID) Fc fusion. Panel E: LIFR CBMI-Ig-like CBMII domain (VPRVVAID)-gp130 CBM domain (ELDME) Fc fusion. This is a homodimer, with LIFR and gp130 fused using a 5x Gly4Ser linker. Panel F: LIFR CBMI-Ig-like CBMII domain (VPRVVAID)-gp130 CBM domain (ELDME) heterodimeric Fc fusion. This variant has LIFR on one arm of the Fc and gp130 on the other arm of the Fc. All variants were successfully expressed and purified. [Figure 10] Binding of purified LIF inhibitors. LIFR CBMI-Ig-like CBMII wild-type Fc fusion (circles), LIFR CBMI-Ig-like CBMII(VPRVVAID) Fc fusion (triangles), and LIFR CBMI-Ig-like CBMII(VPRVVAID)-gp130 CBM(ELDME) Fc fusion (diamonds) bind to soluble human LIF as measured using KinExA. KD values ​​were calculated from the KinExA software and fitted curves are shown. [Figure 11]Homodimeric LIF inhibitors bind to multiple LIFs at once. Panel A: Schematic of the multiple LIF binding assay. LIF is displayed on the yeast surface. Inhibitors are incubated at saturating concentrations and excess is washed away. LIF-His is then incubated with inhibitor-bound yeast at concentrations of 10 nM and 100 nM. Binding is detected via the His-tag domain of LIF, which should only be present if the inhibitor can bind to multiple LIFs at once and act as a "bridge". Panel B: Results from multiple LIF binding experiments. LIF was displayed on yeast and LIFR-WT-Fc, LIFR-VPRVVAID-Fc, LIFR-gp130 fusion-Fc, or anti-LIF mAb, L1, was used as a binding bridge between displayed LIF-His and soluble LIF-His. Fluorescence emission from anti-His fluorescent antibody in each condition was normalized to a control with no added LIF-His. [Figure 12] When binding to LIF in the presence of competitors, recombinant inhibitors show improved off-rates compared to WT. Panel A: Schematic of competitive LIF binding assay. LIF is displayed on the yeast surface. Inhibitors are incubated at saturating concentrations and excess is washed away. LIF-His is then incubated with inhibitor-bound yeast at concentrations of 10 nM and 100 nM. Binding is detected via the Fc domain of the inhibitor Fc fusion, which is competitively displaced from yeast-displayed LIF by high concentrations of soluble LIF-His. Panel B: Results from competitive LIF binding experiments. LIF was displayed on yeast and LIFR-WT-Fc, LIFR-VPRVVAID-Fc, LIFR-gp130 fusion-Fc, or anti-LIF mAb, L1, were added as binding partners. Excess inhibitor was washed away and soluble LIF was added as competitor for 24 h. Fluorescence emission from the anti-Fc fluorescent antibody in each condition was normalized to a control in which excess inhibitor was not removed and no soluble LIF was added. [Figure 13]LIF inhibitors bind simultaneously to LIF. Panel A: Schematic of the simultaneous binding assay. gp130 (shown) and LIFR are displayed on the yeast surface. LIF is incubated at saturating concentrations and excess is washed away. The inhibitor (LIFR-VPRVVAID-Fc shown) is then co-cultured with the LIF-bound yeast. Binding is detected via the Fc domain of the inhibitor, which should only be present if simultaneous receptor binding occurs using LIF as a "bridge". Panel B: Results from a simultaneous binding experiment. Either LIFR or gp130 was displayed on yeast and human LIF was used as a binding bridge. Fluorescence emission is the reading of an anti-Fc fluorescent antibody normalized to a control with no added LIF. Simultaneous binding of LIFR-VPRVVAID-Fc, gp130-ELDME-Fc, LIFR-gp130 heterodimer-Fc, LIFR-gp130 homodimer fusion-Fc, anti-LIF mAb L1, and anti-LIF mAb G1 is shown. [Figure 14] LIF inhibitors compete off LIF from the wild-type receptor. Panel A: Schematic of the competitive binding assay. Wild-type gp130 or LIFR (indicated) are displayed on the yeast surface. Human LIF-His is incubated at saturating concentrations. Inhibitors (LIFR-VPRVVAID-Fc shown) are then co-cultured in excess with LIF-bound yeast. LIF binding is detected via the His6-tag on LIF. The less LIF that remains bound after inhibitor incubation, the better the inhibitor is at competing off LIF from the WT receptor. Panel B: Results from a competitive binding experiment. Either wild-type LIFR or gp130 were displayed on yeast and saturated with human LIF-His. Percent bound is the fluorescence emission detected from LIF-His normalized to no inhibitor added. Competitive binding of LIFR-WT-Fc, gp130-ELDME-Fc (recombinant), LIFR-VPRVVAID-Fc (recombinant), LIFR-gp130 fusion-Fc (recombinant), LIFR-gp130 heterodimer-Fc (recombinant), anti-LIF mAb L1, and anti-LIF mAb G1 is shown. [Figure 15]Recombinant inhibitors block downstream STAT3 signaling in HeLa luciferase reporter cells. Panel A: Schematic of LIF signaling in HeLa reporter cells. LIF promotes dimerization of LIFR with gp130, leading to phosphorylation of STAT3, activation of downstream signaling, and ultimately production of luciferase under the control of STAT3 response elements. Panel B: Inhibition of LIF-derived luciferase activity by different concentrations of LIFR VPRVVAID Fc, LIFR-gp130 fusion recombinant Fc, and LIFR WT Fc. Panel C: LIF-derived luciferase signal upon delayed addition of LIFR Fc or fusion Fc. Panel D: Inhibition of LIF-derived luciferase activity across orders of magnitude. LIFR VPRVVAID Fc IC50=35pM, 53-fold improvement over LIFR WT Fc. Panel E: Cartoon representation - LIFR binding to IL-6 family members LIF and OSM. Graph - Measurement of luciferase signal derived from LIF or OSM incubated with LIFR VPRVVAID Fc or LIFR WT Fc. [Figure 16] LIF inhibitors ablate LIF signaling in pancreatic cancer cells. Panel A: Schematic of LIF signaling. LIF binds to LIFR and gp130, causing heterodimerization of the receptors. Dimerization recruits JAKs, which phosphorylate STAT3 on tyrosine 705. This leads to STAT3 dimerization, nuclear entry, and activation of transcriptional programming. Thus, pSTAT3-Y705 is a readout for LIF signaling. Panel B: Western blot of PANC1 (human pancreatic cancer cell line) lysates exposed to 135 pM human LIF and different concentrations of LIFR-VPRVVAID-Fc (recombinant), LIFR-WT-Fc, LIFR-VPRVVAID-gp130-ELDME Fc, and L1 anti-LIF mAb. Panel C: Quantification of pSTAT3 signal, normalized to tubulin signal. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] Soluble leukemia inhibitory factor receptor (LIFR) polypeptides, soluble glycoprotein 130 (gp130) polypeptides, and soluble fusion proteins and dimers comprising such polypeptides are provided. The soluble polypeptides bind to leukemia inhibitory factor (LIF). In certain embodiments, the soluble polypeptides show increased binding affinity to LIF compared to the corresponding wild-type polypeptide. Nucleic acids encoding such soluble polypeptides, expression vectors comprising such nucleic acids, and cells comprising such nucleic acids and / or expression vectors are also provided. Methods of using the soluble polypeptides are also provided, including methods of inhibiting LIF activity in individuals in need of inhibition of LIF activity (e.g., to treat cancer).

[0009] Before describing the soluble polypeptides, nucleic acids, expression vectors, cells and methods of the present disclosure in more detail, it should be understood that the soluble polypeptides, nucleic acids, expression vectors, cells and methods are not limited to the specific embodiments described, and can of course be modified.It should also be understood that the terms used herein are only for describing specific embodiments, and are not intended to be limiting, since the scope of the soluble polypeptides, nucleic acids, expression vectors, cells and methods is limited only by the scope of the appended claims.

[0010] Where a range of values ​​is provided, it is understood that, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, each intervening value is between the upper and lower limits of that range, and any other stated or intervening values ​​within that stated range are encompassed within the soluble polypeptides, nucleic acids, expression vectors, cells and methods. The upper and lower limits of these smaller ranges may be independently included within the smaller ranges, and are also encompassed within the soluble polypeptides, nucleic acids, expression vectors, cells and methods, subject to any specific excluded limit within the stated range. Where a stated range includes one or both of the limits, ranges excluding either or both of those included limits are also encompassed within the soluble polypeptides, nucleic acids, expression vectors, cells and methods.

[0011] Certain ranges are presented herein with the term "about" preceding the numerical values. The term "about" is used herein to provide literal support for the exact number it precedes, as well as a number that is close to or approximately the number it precedes. In determining whether a number is close to or approximately equal to a particular recited number, the approximate or approximating unrecited number may be a number that is substantially equivalent to the specifically recited number in the context in which it is presented.

[0012] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the soluble polypeptide, nucleic acid, expression vector, cell and method belong. Any soluble polypeptide, nucleic acid, expression vector, cell and method similar or equivalent to those described herein can also be used in the practice or testing of the soluble polypeptide, nucleic acid, expression vector, cell and method, but representative exemplary soluble polypeptide, nucleic acid, expression vector, cell and method are described here.

[0013] All publications and patents cited herein are incorporated by reference as if each individual publication or patent was specifically and individually indicated to be incorporated by reference, and are incorporated by reference herein to disclose and describe the related methods and / or materials for which the publications are cited. The citation of any publication is for its disclosure prior to the filing date, and should not be construed as an admission that the soluble polypeptides, nucleic acids, expression vectors, cells and methods of the present invention are not entitled to antedate such publication, since the publication dates provided may be different from the actual publication dates, which may need to be independently confirmed.

[0014] It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should be further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as a precedent for the use of exclusive terminology such as "solely," "solely," and the like, or the use of "negative" limitations in connection with the recitation of claim elements.

[0015] It is recognized that certain features of the soluble polypeptides, nucleic acids, expression vectors, cells and methods described in the context of separate embodiments for clarity can also be provided in combination in a single embodiment. Conversely, various features of the soluble polypeptides, nucleic acids, expression vectors, cells and methods described in the context of a single embodiment for brevity can be provided separately or in any suitable subcombination. All combinations of the embodiments are specifically encompassed by the present disclosure and are disclosed herein as if each and every combination were individually and explicitly disclosed, to the extent that such combinations encompass the process and / or composition that can be performed. In addition, all subcombinations listed in the embodiments that describe such variables are also specifically encompassed by the soluble polypeptides, nucleic acids, expression vectors, cells and methods of the present invention and are disclosed herein as if each and every such subcombination were individually and explicitly disclosed.

[0016] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has individual components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the methods of the present disclosure. Any recited method may be carried out in the order of events recited or in any other order which is logically possible.

[0017] Soluble Polypeptides As summarized above, the embodiments of the present disclosure include soluble polypeptides. The soluble polypeptides bind to leukemia inhibitory factor (LIF) (UniProtKB-P15018 (human) and UniProtKB-P09056 (mouse)) and inhibit LIF activity. LIF is a multifunctional cytokine, whose receptors include leukemia inhibitory factor receptor (LIFR) (UniProtKB-P42702 (human) and UniProtKB-P42703 (mouse)) and glycoprotein 130 (gp130) (UniProtKB-P40189 (human) and UniProtKB-Q00560 (mouse)).

[0018] As shown diagrammatically in Figure 1, Figure 15 Panel A, and Figure 16 Panel A, LIF binds to LIFR and gp130, causing heterodimerization of the receptors. Dimerization recruits JAKs, which phosphorylate STAT3 on tyrosine 705. This leads to STAT3 dimerization, nuclear entry, and activation of transcriptional programming.

[0019] The polypeptides of the present invention find use in a variety of contexts based on the extracellular (and therefore soluble) portion of LIFR and / or gp130. For example, soluble polypeptides find use as therapeutics when administered to individuals in need of inhibition of LIF activity, for example, individuals with cancer or other medical conditions for which inhibition of LIF activity is beneficial. Soluble polypeptides can be used as "decoy" receptors that act as "traps" for LIF ligands, so that the availability of LIF to bind to its natural receptor on the surface of cells (e.g., cancer cells) is substantially reduced or eliminated, thereby reducing or eliminating LIF activity / signaling. A schematic diagram of such a LIF ligand trap according to one embodiment is shown in FIG. 2. In this example, the soluble polypeptide is dimerized, with each monomer of this dimer comprising a LIFR portion 202 (here comprising the first three domains of human LIFR (cytokine binding motif I-Ig-like-cytokine binding motif II)) fused (directly or indirectly) to a fragment crystallizable (Fc) domain 208 (e.g., human IgG1 Fc domain, mouse IgG2a Fc domain, etc.). As shown in FIG. 2, the dimer acts as a LIF ligand trap that sequesters LIF from its native LIFR and gp130 receptor on the surface of the cell 210, thereby inhibiting LIF signaling / activity. The soluble polypeptides of the present disclosure also find use in diagnostic applications, for example, to detect LIF as a biomarker for cancer (e.g., pancreatic cancer) detection, and in research applications, for example, to inhibit LIF signaling / activity to determine the biological effects of LIF. The soluble polypeptides of the present disclosure will now be described in more detail.

[0020] Soluble LIFR Polypeptides The present disclosure provides soluble LIFR polypeptides. By "soluble LIFR polypeptide" is meant a LIFR polypeptide that is not incorporated into a cell membrane, for example because the soluble LIFR polypeptide comprises only the extracellular portion of LIFR or a fragment thereof. In some embodiments, the soluble LIFR polypeptide comprises, consists essentially of, or consists of the first three domains of LIFR, which are, in order from N-terminus to C-terminus, (1) cytokine binding motif I (CBMI) domain, (2) Ig-like domain, and (3) cytokine binding motif II (CBMII) domain. The amino acid sequence of wild-type human LIFR (excluding the signal sequence) is shown in Table 1 below. The underlined amino acids constitute the CBMI, Ig-like, and CBMII domains. [Table 1]

[0021] In certain embodiments, a soluble LIFR polypeptide of the disclosure comprises an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO:2, or a LIF-binding fragment thereof that comprises 400-489, 420-489, 440-489, 460-489, 470-489, 475-489, 480-489, or 485-489 consecutive amino acids of the amino acid sequence set forth in SEQ ID NO:2.

[0022] A soluble LIFR polypeptide may have a wild-type LIFR amino acid sequence. In other aspects, a soluble LIFR polypeptide is a "variant" that includes one or more conservative amino acid substitutions, one or more amino acid substitutions that increase the binding affinity for LIF compared to the corresponding wild-type LIFR polypeptide (e.g., one or more of any of the amino acid substitutions described herein that increase the binding affinity of LIFR for LIF), or a combination thereof. As used herein, a "conservative substitution" is one in which an amino acid is replaced with another amino acid having similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to remain substantially unchanged. Modifications may be made in the polynucleotide and polypeptide structures envisioned in certain embodiments, including polypeptides that have at least approximately and still obtain functional molecules that encode variant or derivative polypeptides with desired characteristics. If it is desired to change the amino acid sequence of a polypeptide to create an equivalent or even improved variant polypeptide, one skilled in the art can, for example, change one or more of the codons of the encoding DNA sequence.

[0023] As summarized above, a soluble LIFR polypeptide of the present disclosure may comprise an amino acid sequence that is at least 70% identical to SEQ ID NO:2, where the LIFR polypeptide exhibits increased binding affinity for LIF compared to a corresponding wild-type LIFR polypeptide. As used herein, a "corresponding" wild-type polypeptide is a parent wild-type polypeptide (derived from human, mouse, etc.) that has been engineered to contain one or more affinity-increasing amino acid substitutions.

[0024] As used herein, "increased binding affinity" refers to a soluble LIFR polypeptide or a soluble gp130 polypeptide that exhibits stronger binding to LIF (lower K DBy "binding affinity" we mean the binding affinity of a soluble LIFR or gp130 polypeptide to LIF (represented by a value). Methods are available for measuring the binding affinity of a soluble LIFR or gp130 polypeptide to LIF. For example, surface plasmon resonance (SPR) technology (e.g., using a BIAcore™ 2000 instrument), KinExA® binding equilibrium exclusion assay (Sapidyne Instruments), Bio-Layer Interferometry (BLI) technology (e.g., ForteBio Octet®), or other similar assays / techniques may be used to determine whether a soluble LIFR or gp130 polypeptide exhibits a desired binding affinity. Suitable techniques for measuring binding affinity in the context of the present disclosure include, for example, those described in Hunter, SA and Cochran, JR (2016) Methods Enzymol. 580:21-44.

[0025] In some embodiments, in a direct binding assay, the equilibrium binding constant (K D ) may be measured using soluble LIFR or gp130 polypeptides conjugated to a fluorophore or radioisotope, or soluble LIFR or gp130 polypeptides containing N- or C-terminal epitope tags for detection by labeled antibodies. If labels or tags are not feasible or desirable, competitive binding assays can be used to determine the half-maximal inhibitory concentration (IC), which is the amount of unlabeled soluble LIFR or gp130 polypeptide at which 50% of the maximal signal of the labeled competitor is detectable. 50 ) can then be determined. 50 Value to K D The value can be calculated.

[0026] In certain embodiments, a soluble LIFR polypeptide having increased binding affinity for LIF comprises one or both of an amino acid substitution at position L218 and an amino acid substitution at position N277, where the position identifications are relative to SEQ ID NO: 2. Non-limiting examples of amino acid substitutions at positions L218 and N277 include one or both of an L218P amino acid substitution and an N277D amino acid substitution.

[0027] In some embodiments, a soluble LIFR polypeptide having increased binding affinity for LIF comprises one, two, or each of an amino acid substitution at position I257, an amino acid substitution at position V262, and an amino acid substitution at position T273, where the position identifications are with respect to SEQ ID NO: 2. Examples of amino acid substitutions at positions I257, V262, and T273 include, but are not limited to, one, two, or each of an I257V amino acid substitution, a V262A amino acid substitution, and a T273I amino acid substitution.

[0028] In certain embodiments, a soluble LIFR polypeptide having increased binding affinity for LIF comprises one, two, or each of an amino acid substitution at position I217, an amino acid substitution at position H240, and an amino acid substitution at position I260, where the position identifications are with respect to SEQ ID NO: 2. Non-limiting examples of amino acid substitutions at positions I217, H240, and I260 include one, two, or each of an I217V amino acid substitution, an H240R amino acid substitution, and an I260V amino acid substitution.

[0029] In some embodiments, a soluble LIFR polypeptide having increased binding affinity for LIF comprises an amino acid substitution at position N242, where the position identification is relative to SEQ ID NO: 2. A non-limiting example of an N242 amino acid substitution is the N242D amino acid substitution.

[0030] In certain embodiments, a soluble LIFR polypeptide of the disclosure comprises an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO:2, or a LIF-binding fragment thereof comprising 400-489, 420-489, 440-489, 460-489, 470-489, 475-489, 480-489, or 485-489 consecutive amino acids of the amino acid sequence set forth in SEQ ID NO:2, wherein the soluble LIFR polypeptide comprises one or more amino acid substitutions at any of positions I217, L218, H240, I257, I206, V262, T271, and N277, in any combination.

[0031] In some embodiments, a soluble LIFR polypeptide of the disclosure comprises an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO:2, or a sequence that is at least 400-489, 420-489, 440-489, 460-489, 470-489, 475-489, 480-489, or 485-489 consecutive amino acids of the amino acid sequence set forth in SEQ ID NO:2. Soluble LIFR polypeptides, including LIF-binding fragments thereof comprising a nucleotide sequence comprising at least one of the amino acids 1 to 6, include one or more of any of the amino acid substitutions described herein that increase the binding affinity of LIFR for LIF, e.g., one, two, three, four, five, six, seven, or each of the amino acid substitutions I217V, L218P, H240R, I257V, I206V, V262A, T271I, and N277D, in any combination, as described elsewhere herein.

[0032] Soluble gp130 Polypeptides Soluble gp130 polypeptides are also provided by the present disclosure. "Soluble gp130 polypeptide" refers to a gp130 polypeptide that is not integrated into a cell membrane, for example, because the soluble gp130 polypeptide comprises only the extracellular portion of gp130 or a fragment thereof. In some embodiments, the soluble gp130 polypeptide comprises, consists essentially of, or consists of the cytokine binding motif (CBM) domain of gp130. The amino acid sequence of wild-type human gp130 (excluding the signal sequence) is shown in Table 2 below. The underlined amino acids constitute the CBM domain. [Table 2]

[0033] In certain aspects, a soluble gp130 polypeptide of the present disclosure comprises an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO:4, or a LIF-binding fragment thereof that comprises 150-200, 160-200, 170-200, 180-200, 185-200, 190-200, or 195-200 consecutive amino acids of the amino acid sequence set forth in SEQ ID NO:4.

[0034] A soluble gp130 polypeptide may have a wild-type gp130 amino acid sequence, hi other embodiments, a soluble gp130 polypeptide is a "variant" that includes one or more conservative amino acid substitutions, one or more amino acid substitutions that increase the binding affinity for LIF compared to the corresponding wild-type gp130 polypeptide (e.g., one or more of any of the amino acid substitutions described herein that increase the binding affinity of gp130 for LIF), or a combination thereof.

[0035] As summarized above, a soluble gp130 polypeptide of the present disclosure may comprise an amino acid sequence that is at least 70% identical to SEQ ID NO:4, wherein the gp130 polypeptide exhibits increased binding affinity for LIF compared to the corresponding wild-type gp130 polypeptide.

[0036] In some embodiments, a soluble gp130 polypeptide with increased binding affinity for LIF comprises an amino acid substitution at position K45, where the position identification is with respect to SEQ ID NO: 4. A non-limiting example of an amino acid substitution at position K45 is a K45E amino acid substitution.

[0037] In certain embodiments, a soluble gp130 polypeptide having increased binding affinity for LIF comprises one or both of an amino acid substitution at position Y95 and an amino acid substitution at position K184, where the position identifications are relative to SEQ ID NO: 4. Non-limiting examples of amino acid substitutions at positions Y95 and K184 include one or both of an Y95D amino acid substitution and a K184E amino acid substitution.

[0038] In some embodiments, a soluble gp130 polypeptide with increased binding affinity for LIF comprises an amino acid substitution at position F46 and one or both of an amino acid substitution at position I130, where the position identifications are relative to SEQ ID NO: 4. Examples of amino acid substitutions at positions F46 and I130 include, but are not limited to, an F46L amino acid substitution and one or both of an I130M amino acid substitution.

[0039] In certain aspects, a soluble gp130 polypeptide of the present disclosure comprises an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO:4, or a LIF-binding fragment thereof comprising 150-200, 160-200, 170-200, 180-200, 185-200, 190-200, or 195-200 consecutive amino acids of the amino acid sequence set forth in SEQ ID NO:4, wherein the soluble gp130 polypeptide comprises one or more amino acid substitutions at any of positions K45, F46, Y95, I130, and K184, in any combination.

[0040] In some embodiments, a soluble gp130 polypeptide of the disclosure comprises an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO:4, or a LIF-binding fragment thereof that comprises 150-200, 160-200, 170-200, 180-200, 185-200, 190-200, or 195-200 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:4, wherein the soluble gp130 polypeptide comprises one or more of any of the amino acid substitutions described herein that increase the binding affinity of gp130 for LIF, e.g., one, two, three, four, or each of the amino acid substitutions K45E, F46L, Y95D, I130M, and K184E, in any combination, as described elsewhere herein.

[0041] Fusion and dimeric proteins Fusion proteins comprising any of the soluble LIFR polypeptides or soluble gp130 polypeptides of the present disclosure are also provided. By "fusion protein" is meant a fusion comprising a soluble LIFR polypeptide or a soluble gp130 polypeptide fused to one or more heterologous polypeptides as part of a single continuous chain of amino acids, which chain is not naturally occurring. In certain embodiments, the one or more heterologous polypeptides are selected from an Fc domain, albumin, transferrin, XTEN, homo-amino acid polymers, proline-alanine-serine polymers, elastin-like peptides, and any combination thereof. In certain embodiments, the fusion protein comprises a soluble LIFR polypeptide fused to a soluble gp130 polypeptide.

[0042] Two or more domains of the fusion protein of the present disclosure may be fused directly or indirectly. For example, a soluble LIFR polypeptide may be indirectly fused to a soluble gp130 polypeptide via a linker. Also, by way of example, a soluble LIFR polypeptide or a soluble gp130 polypeptide may be fused to a heterologous polypeptide (e.g., an Fc domain) via a linker. Suitable linkers include, but are not limited to, peptide linkers. In certain embodiments, the peptide linker is a linker comprising glycine and serine, e.g., a GlySer linker. GlySer linkers of interest include, but are not limited to, (Gly4Ser) n Linkers are included.

[0043] In some embodiments, one or more heterologous polypeptides comprise an Fc domain, such as a human Fc domain or a mouse Fc domain. The Fc domain may be a full-length Fc domain or a fragment thereof. A non-limiting example of a human Fc domain that may be fused to any of the soluble LIFR or gp130 polypeptides of the present disclosure is a human IgG1 Fc domain having the sequence set forth in Table 3 below (SEQ ID NO:5), or a fragment thereof. [Table 3]

[0044] The amino acid sequences (excluding the signal sequence) of exemplary fusion proteins of the disclosure are provided in Table 4. The amino acid sequence of a fusion protein ("gp130 ELDME hIgG1") comprising a gp130 domain (underlined) fused to a human IgG1 Fc domain (italics) via a linker (here, a 3x glycine-serine (GS) linker, wavy underlined) is provided (SEQ ID NO:6). The gp130 domain comprises amino acid substitutions K45E, F46L, Y95D, I130M, and K184E ("ELDME") as described elsewhere herein. This fusion protein corresponds to a monomer of the dimeric protein shown diagrammatically in panel C of FIG. 9. Also provided in Table 4 is the amino acid sequence of a fusion protein ("LIFR VPRVVAID hIgG1") that includes a LIFR cytokine binding motif I (CBMI)-cytokine binding motif II (CBMII) domain (underlined) fused to a human IgG1 Fc domain (italics) via a linker (here, a 3x glycine-serine (GS) linker, wavy underlined) (SEQ ID NO: 7). The LIFR cytokine binding motif I (CBMI)-cytokine binding motif II (CBMII) domain contains the amino acid substitutions I217V, L218P, H240R, I257V, I206V, V262A, T271I, and N277D ("VPRVVAID"), as described elsewhere herein. This fusion protein corresponds to a monomer of the dimeric protein shown diagrammatically in panel D of FIG. 9. Table 4 also provides the amino acid sequence of a fusion protein ("LIFR-gp130 VPRVVAID-ELDME hIgG1") comprising the VPRVVAID LIFR domain (underlined) of the "LIFR VPRVVAID hIgG1" fusion protein fused via a linker (here, a 5x Glycine 4-Serine 1 (G4S) linker, wavy underlined) to the ELDME gp130 domain (double underlined) of the "gp130 ELDME hIgG1" fusion protein, where the ELDME gp130 domain is fused to a human IgG1 Fc domain (italics) via a linker (here, a 3x Glycine-Serine (GS) linker, wavy underlined) (SEQ ID NO:8).This fusion protein corresponds to a monomer of the dimeric protein shown diagrammatically in panel E of FIG. 9. Table 4 further provides the amino acid sequences of the fusion protein monomers of the dimeric protein shown diagrammatically in panel F of FIG. 9. The first monomer comprises the VPRVVAID LIFR domain (underlined) of the "LIFR VPRVVAID hIgG1" fusion protein fused to the human IgG1 Fc knob-in-hole (KiH) CH3A domain (italics) via a linker (here a 3x glycine-serine (GS) linker, wavy underlined) (SEQ ID NO: 9). The second monomer comprises the ELDME gp130 domain (underlined) of the "gp130 ELDME hIgG1" fusion protein fused to the human IgG1 Fc knob-in-hole (KiH) CH3B domain (italics) via a linker (here a 3x glycine-serine (GS) linker, wavy underlined) (SEQ ID NO: 10). [Table 4-1] [Table 4-2] [Table 4-3]

[0045] Also provided are dimeric proteins comprising a soluble LIFR polypeptide, a soluble gp130 polypeptide, or a fusion protein comprising the same (e.g., any of the fusion proteins in Table 4, or a LIF-binding variant thereof) dimerized with a soluble LIFR polypeptide, a soluble gp130 polypeptide, or a fusion protein comprising the same. In some embodiments, each monomer is a fusion protein comprising an Fc domain, and dimerization of the monomers is via the Fc domain. Exemplary dimeric proteins of the disclosure include those described in the Experimental Section below and those shown diagrammatically in FIG. 9.

[0046] Recombinant / development and production of soluble LIFR and gp130 polypeptides Methods for recombining / developing additional soluble LIFR or gp130 polypeptides with one or more desired functionalities are also provided by the present disclosure. The manner in which soluble LIFR or gp130 polypeptides are developed may vary. Rational and combinatorial approaches can be used to recombine soluble LIFR and gp130 polypeptides with novel properties, such as increased binding affinity and / or specificity for LIF. For example, to develop soluble LIFR or gp130 polypeptides, libraries of soluble LIFR or gp130 polypeptides may be created and screened, for example, by bacterial display, phage display, yeast surface display, fluorescence activated cell sorting (FACS), and / or any other suitable screening method.

[0047] Yeast surface display is a powerful combinatorial technique that has been used to design proteins with novel molecular recognition properties, increased target binding affinity, proper folding, and improved stability. In this platform, libraries of protein variants are generated and screened in a high-throughput manner to isolate variants with desired biochemical and biophysical properties. As shown in the experimental section below, we have successfully used yeast surface display to engineer soluble LIFR and gp130 polypeptides with increased binding affinity for LIF. Yeast surface display benefits from the eukaryotic secretory pathway, chaperone-assisted folding, and quality control mechanisms of efficient disulfide bond formation.

[0048] One exemplary method for developing soluble LIFR or gp130 polypeptides with desired properties of interest involves genetically fusing the soluble LIFR or gp130 polypeptide to the yeast mating agglutinin protein Aga2p, which is connected by two disulfide bonds to the yeast cell wall protein Aga1p. This Aga2p fusion construct, and the Aga1p expression cassette integrated into the chromosome, can be expressed under the control of a suitable promoter, such as a galactose-inducible promoter. N- or C-terminal epitope tags can be included to measure cell surface expression levels by flow cytometry using fluorescently labeled primary or secondary antibodies. This construct represents the most widely used display format, in which the N-terminus of the soluble LIFR or gp130 polypeptide may be fused to Aga2p, although several alternative variations of yeast surface display plasmids have been described and may be used to develop the soluble LIFR or gp130 polypeptides of the present disclosure. One advantage of this screening platform over panning-based methods used in phage or mRNA display is that two-color FACS can be used to quantitatively distinguish clones that differ as little as two-fold in binding affinity for a particular target.

[0049] To selectively mutate LIFR or gp130 at the DNA level, one approach is error-prone PCR, which can be used to introduce mutations by any number of altered reaction conditions, including using a polymerase that does not have proofreading (i.e., exonuclease) activity, using a mixture of triphosphate derivatives of nucleoside analogs, using altered ratios of dNTPs, varying magnesium or manganese concentrations, etc. Alternatively, degenerate codons can be introduced by oligonucleotide assembly, for example, using overlap extension PCR. Genetic material can then be amplified using flanking primers that overlap sufficiently with the yeast display vector for homologous recombination in yeast. These methods allow for the creation of LIFR or gp130 libraries at relatively low cost and with little labor. Synthetic libraries and modern methods have been developed that allow for defined control over library composition.

[0050] In certain embodiments, the display library (e.g., yeast display library) is screened for binding to the target of interest (e.g., LIF) by FACS. Two-color FACS may be used for library screening, where one fluorescent label can be used to detect the c-myc epitope tag and the other can be used to measure the interaction of the soluble LIFR or gp130 polypeptide to the binding label of interest. Different instrument lasers and / or filter sets can be used to measure the excitation and emission properties of the two fluorophores at single-cell resolution. This allows for normalization of yeast expression levels with binding. That is, soluble LIFR or gp130 polypeptides that show low yeast expression but bind to abundant targets can be distinguished from soluble LIFR or gp130 polypeptides that are expressed at high levels but bind weakly to the target. Thus, in a two-dimensional flow cytometry plot of binding versus expression, a population of yeast cells that bind to the target antigen appears on the diagonal. High affinity binders can be isolated using library sorting gates. Alternatively, it may be useful in early sorting rounds to remove from the library unwanted clones that do not express polypeptides of the desired length.

[0051] After enrichment of soluble LIFR or gp130 polypeptide library for clones encoding soluble LIFR or gp130 polypeptide of interest, yeast plasmid is recovered and sequenced.Under high selection stringency, further rounds of FACS can be carried out.Then, the binding affinity or dynamic off-rate of LIFR or gp130 polypeptide clones displayed in yeast can be measured.

[0052] Once the LIFR or gp130 polypeptide of interest has been identified by surface display (e.g., yeast surface display), recombinant soluble LIFR or gp130 polypeptide, or any fusion protein comprising same, may be produced using suitable methods. In certain aspects, soluble LIFR or gp130 polypeptide, or any fusion protein comprising same, is produced using recombinant DNA approaches. Strategies have been developed for producing polypeptides using recombinant methods in various host cell types. For example, functional soluble LIFR or gp130 polypeptide may be produced using barnase as a gene fusion partner, which promotes folding in the E. coli periplasmic space and serves as a useful purification handle. According to certain embodiments, recombinant soluble LIFR or gp130 polypeptide is expressed in yeast (e.g., yeast strains Pichia pastoris or Saccharomyces cerevesiae) or mammalian cells (e.g., human embryonic kidney cells or Chinese hamster ovary cells). The expression construct may encode one or more tags (e.g., a C-terminal hexahistidine tag for purification by metal chelate chromatography (Ni-NTA). Size exclusion chromatography can then be used to remove aggregates, misfolded multimers, etc.

[0053] Aspects of the present disclosure include nucleic acids encoding the soluble LIFR and gp130 polypeptides of the present disclosure (and any fusion proteins containing the same). That is, nucleic acids encoding any of the soluble LIFR or gp130 polypeptides of the present disclosure or fusion proteins containing any of the soluble LIFR or gp130 polypeptides described herein are provided. In certain embodiments, such nucleic acids are present in an expression vector. The expression vector comprises a promoter operably linked to the nucleic acid encoding the agent (e.g., a soluble LIFR or gp130 polypeptide), and the promoter is selected based on the type of host cell selected to express the agent. Suitable expression vectors are typically replicable within the host organism as episomes or as an integrated part of the host chromosomal DNA. Generally, expression vectors include a selection marker (e.g., ampicillin resistance, hygromycin resistance, tetracycline resistance, kanamycin resistance, neomycin resistance, etc.) to allow detection of those cells transformed with the desired DNA sequence.

[0054] Also provided are host cells comprising any of the soluble LIFR or gp130 polypeptides described herein and comprising a nucleic acid encoding any of the soluble LIFR or gp130 polypeptides of the present disclosure, as well as any expression vectors comprising the same. Escherichia coli is an example of a prokaryotic host cell that can be used to clone a nucleic acid encoding a soluble LIFR or gp130 polypeptide of the present disclosure. Other microbial hosts suitable for use include bacilli such as Bacillus subtilis, and other Enterobacteriaceae such as Salmonella, Serratia, and various Pseudomonas species. In these prokaryotic hosts, expression vectors can also be made, which typically will contain expression control sequences (e.g., origins of replication) compatible with the host cell. In addition, there will be any number of a variety of well-known promoters, such as the lactose promoter system, the tryptophan (trp) promoter system, the β-lactamase promoter system, or a promoter system derived from lambda phage. The promoters will typically control expression, optionally with an operator sequence, and will have ribosome binding site sequences, etc., for initiating and completing transcription and translation.

[0055] Other microbes, such as yeast, are also useful for expression. Saccharomyces (e.g., S. cerevisiae) and Pichia are examples of suitable yeast host cells containing suitable vectors with expression control sequences (e.g., promoters), origins of replication, termination sequences, etc., as appropriate. Typical promoters include 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, among others, promoters from alcohol dehydrogenase, isocytochrome C, and enzymes involved in maltose and galactose utilization.

[0056] In addition to microorganisms, mammalian cells (e.g., mammalian cells grown in in vitro cell culture) can also be used to express and produce the soluble LIFR and gp130 polypeptides of the present disclosure. Suitable mammalian host cells include human cell lines, non-human primate cell lines, rodent (e.g., mouse, rat) cell lines, and the like. Suitable mammalian cell lines include, but are not limited to, HeLa cells (e.g., American Type Culture Collection (ATCC) No. CCL-2), CHO cells (e.g., ATCC Nos. CRL9618, CCL61, CRL9096), 293 cells (e.g., ATCC No. CRL-1573), Vero cells, NIH 3T3 cells (e.g., ATCC No. CRL-1658), Huh-7 cells, BHK cells (e.g., ATCC No. CCL10), PC12 cells (ATCC No. CRL1721), COS cells, COS-7 cells (ATCC No. CRL1651), RAT1 cells, mouse L cells (ATCC No. CCLI.3), human embryonic kidney (HEK) cells (ATCC No. CRL1573), HLHepG2 cells, and the like. Expression vectors for these cells may contain expression control sequences such as replication origins, promoters, and enhancers, as well as necessary processing information sites such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcription terminator sequences. Examples of suitable expression control sequences are promoters derived from immunoglobulin genes, SV40, adenovirus, bovine papilloma virus, cytomegalovirus, and the like.

[0057] Once synthesized (e.g., recombinantly), soluble LIFR or gp130 polypeptides may be purified according to standard procedures known in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, high performance liquid chromatography (HPLC) purification, gel electrophoresis, etc. A subject soluble LIFR or gp130 polypeptide may be substantially pure, e.g., at least about 80%-85% pure, at least about 85%-90% pure, at least about 90%-95% pure, or 98%-99% or more pure, e.g., free of contaminating materials such as cellular debris, macromolecules other than the soluble LIFR or gp130 polypeptide.

[0058] composition Compositions comprising the soluble LIFR and / or soluble gp130 polypeptides of the present disclosure (including any fusion and / or dimeric proteins containing them) are also provided.

[0059] In certain aspects, a composition comprises a soluble LIFR and / or soluble gp130 polypeptide of the present disclosure present in a liquid medium. The liquid medium may be an aqueous liquid medium such as water, a buffer solution, etc. One or more additives may be present in such compositions, such as salts (e.g., NaCl, MgCl2, KCl, MgSO4), buffers (Tris buffer, N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), 2-(N-morpholino)ethanesulfonic acid (MES), 2-(N-morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-morpholino)propanesulfonic acid (MOPS), N-tris[hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS), etc.), protease inhibitors, glycerol, etc.

[0060] Pharmaceutical compositions are also provided. Pharmaceutical compositions include the soluble LIFR polypeptide, soluble gp130 polypeptide, fusion protein, and / or dimerization protein of the present disclosure (any of which may be referred to herein as "LIF binding agent") and a pharma- ceutical acceptable carrier. Pharmaceutical compositions generally include a therapeutically effective amount of LIF binding agent. "Therapeutically effective amount" refers to a dosage amount sufficient to produce a desired result, for example, an amount sufficient to produce a beneficial or desired therapeutic (including prophylactic) effect, such as reducing cell proliferation in an individual with a cell proliferation disorder associated with LIF signaling (e.g., cancer, e.g., pancreatic cancer).

[0061] The LIF binding agent of the present disclosure can be incorporated into various preparations for therapeutic administration.More specifically, the LIF binding agent can be formulated into pharmaceutical composition by combining with suitable pharmaceutically acceptable excipient or diluent, and can be formulated into solid, semi-solid, liquid or gas form preparations such as tablets, capsules, powders, granules, ointments, liquids, injections, inhalants and aerosols.

[0062] Formulations of the LIF binding agents of the present disclosure suitable for administration to an individual (e.g., suitable for human administration) will generally be sterile and may further be free of detectable pyrogens or other contaminants that would contraindicate administration to an individual according to a selected route of administration.

[0063] In pharmaceutical dosage forms, the LIF binding agent can be administered alone or in appropriate association and combination with other pharma- ceutical active compounds. The following methods and excipients are merely examples and are in no way limiting.

[0064] For oral formulations, the LIF binder may be used alone or in combination with suitable excipients, e.g., conventional excipients such as lactose, mannitol, corn starch or potato starch; binders such as microcrystalline cellulose, cellulose derivatives, acacia, corn starch or gelatin; disintegrants such as corn starch, potato starch or sodium carboxymethylcellulose; lubricants such as talc or magnesium stearate; and, as desired, diluents, buffers, wetting agents, preservatives and flavorings to produce tablets, powders, granules or capsules.

[0065] The LIF binder can be formulated into an injectable preparation by dissolving, suspending or emulsifying the LIF binder in an aqueous or non-aqueous solvent such as vegetable oil or other similar oil, synthetic fatty acid glyceride, ester of higher fatty acid, or propylene glycol, and, if desired, with conventional additives such as solubilizers, isotonicity agents, suspending agents, emulsifiers, stabilizers and preservatives.

[0066] The pharmaceutical composition may be in liquid form, lyophilized form, or liquid form reconstituted from lyophilized form, and lyophilized formulation should be reconstituted with sterile solution before administration.The standard procedure for reconstituting lyophilized composition is to add back a certain amount of pure water (typically equivalent to the volume removed during lyophilization), but a solution containing antibacterial agent may be used to produce pharmaceutical composition for parenteral administration.

[0067] Aqueous formulations of LIF binders can be prepared, for example, in a pH buffer ranging from about 4.0 to about 7.0, or from about 5.0 to about 6.0, or alternatively at about pH 5.5. Examples of buffers suitable for a pH within this range include phosphate buffers, histidine buffers, citrate buffers, succinate buffers, acetate buffers and other organic acid buffers. The buffer concentration can be, for example, from about 1 mM to about 100 mM, or from about 5 mM to about 50 mM, depending on the buffer and the desired tonicity of the formulation.

[0068] How to use Methods of using the disclosed soluble LIFR polypeptide, soluble gp130 polypeptide, fusion protein, and / or dimerization protein (all of which may be referred to herein as "LIF-binding agent") are also provided. According to certain embodiments, methods are provided that include administering to an individual in need of inhibition of LIF activity a therapeutically effective amount of the disclosed soluble LIFR polypeptide, soluble gp130 polypeptide, fusion protein, and / or dimerization protein, or any such LIF-binding agent-containing pharmaceutical composition. In certain aspects, the individual in need of inhibition of LIF activity has a cell proliferation disorder associated with LIF signaling, and the administration is effective to treat the cell proliferation disorder. In certain aspects, the cell proliferation disease is cancer. Cancers of interest include, but are not limited to, pancreatic cancer.

[0069] For example, in some embodiments, the LIF-binding agent or pharmaceutical composition of the present disclosure inhibits the growth, metastasis and / or invasion of cancer cells in a host when the LIF-binding agent or pharmaceutical composition is administered in an effective amount. By "cancer cell" is meant a cell that exhibits a neoplastic cell phenotype that can be characterized, for example, by one or more of aberrant cell growth, aberrant cell proliferation, loss of density-dependent growth inhibition, anchorage-independent growth capacity, ability to promote tumor growth and / or development in immunocompromised non-human animal models, and / or any suitable indicator of cell transformation. As used herein, "cancer cell" may be used interchangeably with "tumor cell," "malignant cell," or "cancerous cell," and includes cancer cells such as solid tumors, semi-solid tumors, primary tumors, metastatic tumors, etc.

[0070] Cancers treatable using the methods of the present disclosure include, but are not limited to, solid tumors, lung cancer (e.g., non-small cell lung cancer (NSCLC), breast cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma, and any other type of cancer that can be treated using the LIF-binding agents or pharmaceutical compositions of the present disclosure.

[0071] The LIF binding agent can be administered alone (eg, in monotherapy) or in combination with one or more additional therapeutic agents (eg, in combination therapy).

[0072] In some embodiments, an effective amount of a LIF binding agent (or a pharmaceutical composition comprising the same) is an amount that, when administered in one or more doses alone (e.g., in monotherapy) or in combination with one or more additional therapeutic agents (e.g., in combination therapy), is effective to reduce symptoms of a cell proliferative disorder (e.g., cancer) in an individual by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or more compared to the symptoms in the individual in the absence of treatment with the LIF binding agent or pharmaceutical composition.

[0073] In certain embodiments, the methods of the disclosure inhibit the growth, metastasis and / or invasion of cancer cells in an individual when the LIF-binding agent or pharmaceutical composition is administered in an effective amount.

[0074] The LIF binding agent or pharmaceutical composition may be administered to an individual using any available method and route suitable for drug delivery, including in vivo and ex vivo methods, and systemic and local routes of administration. Conventional and pharmacologic acceptable routes of administration include intranasal, intramuscular, intratracheal, subcutaneous, intradermal, topical application, intraocular, intravenous, intraarterial, nasal, oral, and other enteral and parenteral routes of administration. Routes of administration may be combined, if desired, or adjusted depending on the LIF binding agent and / or the desired effect. The LIF binding agent or pharmaceutical composition may be administered in a single dose or multiple doses. In some embodiments, the LIF binding agent or pharmaceutical composition is administered intravenously. In some embodiments, the LIF binding agent or pharmaceutical composition is administered by injection, for example, for systemic delivery (e.g., intravenous infusion) or to a localized site.

[0075] Various individuals can be treated according to the present method. Generally, such subjects are "mammals" or "mammals", which terms are used broadly to describe organisms within the mammalian class, including carnivora (e.g., dogs and cats), rodents (e.g., mice, guinea pigs and rats), and primates (e.g., humans, chimpanzees, and monkeys). In some embodiments, the individual is a human.

[0076] "Treating" or "treatment" refers to at least an amelioration of symptoms associated with a cell proliferative disorder (e.g., cancer) in an individual, where amelioration is used broadly to refer to at least a reduction in a parameter, e.g., the severity of a symptom associated with the cell proliferative disorder being treated. Thus, treatment also includes situations in which a pathological condition or at least a symptom associated therewith is completely suppressed, e.g., prevented from occurring, or halted, e.g., discontinued, such that an individual no longer suffers from the cell proliferative disorder, or at least a symptom characterizing the cell proliferative disorder.

[0077] Dosage depends on the severity and responsiveness of the disease state to be treated. Optimal dosing schedules can be calculated from measurements of drug accumulation in the patient's body. The administering physician can determine the optimal dosage, dosing method and repetition rate. Optimal dosages may vary depending on the relative potency of individual LIF-binding agents, and are generally determined by EC50- ... 50The dosage may be estimated based on the dose. Generally, the dosage is 0.01 μg to 100 g per kg of body weight and may be administered once or more per day, week, month, or year. The treating physician may estimate the repetition rate of administration based on the measured residence time and the concentration of the drug in the body fluids or tissues. After successful treatment, it may be desirable to subject the subject to a maintenance therapy to prevent recurrence of the disease state, and the LIF binding agent or pharmaceutical composition is administered at a maintenance dose ranging from 0.01 μg to 100 g per kg of body weight once or more per day, once every few months, once every six months, once every year, or any other suitable frequency.

[0078] The therapeutic methods of the present disclosure may involve administering to a subject one LIF-binding agent, or may involve administering to a subject two or more LIF-binding agents, by administration of a cocktail of different LIF-binding agents.

[0079] In some embodiments, a method is provided that includes identifying an individual as having a cell proliferation disorder associated with LIF signaling. Identifying an individual as having a cell proliferation disorder associated with LIF signaling can be performed using various approaches and combinations thereof. In certain aspects, identifying is based on LIF abundance in a sample obtained from the individual (e.g., a body fluid sample, a tumor biopsy, etc.). In some embodiments, LIF abundance is quantified using the soluble LIFR polypeptide, soluble gp130 polypeptide, fusion protein, and / or dimerization protein of the present disclosure as a LIF capture agent.

[0080] In certain aspects, the identifying is based on the level of LIF signaling in a sample obtained from an individual. The level of LIF signaling may be based on the phosphorylation state of one or more LIF signaling pathway molecules, including molecules in the Jak-STAT signaling pathway, a non-limiting example of which is pSTAT3 (e.g., pSTAT3-Y705). According to certain embodiments, the identifying is based on immunoassay. A variety of suitable immunoassay formats are available, including ELISA, flow cytometry assay, immunohistochemistry on tissue section samples, immunofluorescence on tissue section samples, Western analysis, and the like.

[0081] In some embodiments, the identifying is based on nucleic acid sequencing. For example, the number of sequencing reads corresponding to the mRNA encoding the protein of interest can be used to determine the expression level of the protein. In certain aspects, the sequencing is performed using a next-generation sequencing system, for example, a sequencing platform provided by Illumina® (e.g., HiSeq™, MiSeq™ and / or Genome Analyzer™ sequencing systems); Oxford Nanopore Technologies (e.g., MinION™, GridIONx5™, PromethION™, or SmidgION™ nanopore sequencing devices), Ion Torrent™ (e.g., Ion PGM™ and / or Ion Proton™ sequencing systems); Pacific Biosciences (e.g., PACBIO RS II sequencing systems); Life Technologies™ (e.g., SOLiD sequencing systems); Roche (e.g., 454 GS FLX+ and / or GS Junior sequencing systems); or any other sequencing platform of interest. Protocols are readily available for isolating nucleic acids from tissue or body fluid samples and for preparing sequencing libraries with sequencing adapters suitable for the desired sequencing platform.

[0082] In some embodiments, the method comprising identifying an individual as having a cell proliferative disorder associated with LIF signaling further comprises obtaining a sample from the individual.

[0083] The sample obtained from an individual may be any sample suitable for determining whether an individual has cell proliferation disorder associated with LIF signal transduction.In certain aspects, the sample is a body fluid sample, such as whole blood, serum, plasma, etc.In some embodiments, the sample is a tissue sample.Tissue samples of interest include, but are not limited to, tumor biopsy samples, etc.

[0084] kit Kits are also provided by the present disclosure. In some embodiments, kits are provided that include pharmaceutical compositions that include any of the soluble LIFR polypeptides, soluble gp130 polypeptides, fusion proteins, and / or dimerization proteins of the present disclosure. The kits may further include instructions for administering the pharmaceutical composition to individuals who need to inhibit LIF activity, such as individuals who have a cell proliferation disorder (e.g., cancer, e.g., pancreatic cancer), or other medical conditions in which inhibition of LIF activity is beneficial. In certain aspects, the kits include pharmaceutical compositions that are present in one or more (e.g., two or more) unit dosage forms.

[0085] In certain aspects, kits are provided that include any of the soluble LIFR polypeptides, soluble gp130 polypeptides, fusion proteins, and / or dimerization proteins of the present disclosure, such kits further including instructions for using them to detect LIF in a sample (e.g., a body fluid sample, a tissue sample, etc.).

[0086] In some embodiments, kits are provided that contain any of the soluble LIFR polypeptides, soluble gp130 polypeptides, fusion proteins, and / or dimerization proteins of the present disclosure, such kits further comprising instructions for using them to inhibit LIF signaling / activity in vitro or in vivo, e.g., for research purposes.

[0087] The components of the kit may be in separate containers, or multiple components may be in a single container. Suitable containers include single tubes (e.g., vials), plates of one or more wells (e.g., 96-well plates, 384-well plates, etc.), and the like.

[0088] The instructions for the kit can be recorded on a suitable recording medium. For example, the instructions can be printed on a substrate such as paper or plastic. As such, the instructions can be present in the kit as a package insert, in the label of the container of the kit or its components (i.e., in association with the packaging or subpackaging), and the like. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer-readable storage medium, such as a portable flash drive, DVD, CD-ROM, diskette, and the like. In still other embodiments, the actual instructions are not present in the kit, but a means is provided for obtaining the instructions from a remote source, for example, via the Internet. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and / or downloaded. As with the instructions, the means for obtaining the instructions are recorded on a suitable substrate.

[0089] Notwithstanding the claims appended hereto, the present disclosure is also defined by the following clauses. 1. A soluble leukemia inhibitory factor receptor (LIFR) polypeptide, comprising an amino acid sequence that is at least 70% identical to SEQ ID NO:2, wherein the LIFR polypeptide exhibits increased binding affinity for leukemia inhibitory factor (LIF) compared to the corresponding wild-type LIFR polypeptide.

[0090] 2. an amino acid substitution at position L218, and an amino acid substitution at position N277, A soluble LIFR polypeptide according to clause 1, wherein the positional identity is relative to SEQ ID NO:2.

[0091] 3. the L218P amino acid substitution, and A soluble LIFR polypeptide according to clause 2, comprising one or both of the following amino acid substitutions:

[0092] 4. Amino acid substitution at position I257, an amino acid substitution at position V262, and an amino acid substitution at position T273, A soluble LIFR polypeptide according to any one of clauses 1 to 3, wherein the positional identification is relative to SEQ ID NO:2.

[0093] 5. I257V amino acid substitution, V262A amino acid substitution, and 5. The soluble LIFR polypeptide of claim 4, comprising one, two or each of the following amino acid substitutions:

[0094] 6. Amino acid substitution at position I217, an amino acid substitution at position H240, and an amino acid substitution at position I260; A soluble LIFR polypeptide according to any one of clauses 1 to 5, wherein the positional identity is relative to SEQ ID NO:2.

[0095] 7. I217V amino acid substitution, H240R amino acid substitution, and 10. The soluble LIFR polypeptide of claim 6, comprising one, two or each of the following amino acid substitutions: I260V, ...

[0096] 8. A soluble LIFR polypeptide according to any one of clauses 1 to 7, comprising an amino acid substitution at position N242, the position identification being relative to SEQ ID NO:2.

[0097] 9. A soluble LIFR polypeptide according to clause 8, comprising an N242D amino acid substitution.

[0098] 10. A soluble LIFR polypeptide according to any one of clauses 1 to 9, comprising an amino acid sequence that is at least 80% identical to SEQ ID NO:2.

[0099] 11. A soluble LIFR polypeptide according to any one of clauses 1 to 9, comprising an amino acid sequence that is at least 90% identical, or at least 95% identical, to SEQ ID NO:2.

[0100] 12. A soluble LIFR polypeptide according to any one of clauses 1 to 11, wherein the soluble LIFR polypeptide is fused to one or more heterologous polypeptides.

[0101] 13. The soluble LIFR polypeptide of clause 12, wherein the one or more heterologous polypeptides comprise a heterologous polypeptide selected from the group consisting of an Fc domain, albumin, transferrin, XTEN, homo-amino acid polymers, proline-alanine-serine polymers, elastin-like peptides, and any combination thereof.

[0102] 14. The soluble LIFR polypeptide according to clause 13, wherein the one or more heterologous polypeptides comprise an Fc domain.

[0103] 15. A soluble LIFR polypeptide according to any one of clauses 12 to 14, wherein the one or more heterologous polypeptides comprise a soluble gp130 polypeptide according to any one of clauses 27 to 38.

[0104] 16. The soluble LIFR polypeptide according to clause 15, wherein the soluble LIFR polypeptide and the soluble gp130 polypeptide are fused via a linker.

[0105] 17. The soluble LIFR polypeptide according to clause 16, wherein the linker comprises a GlySer linker.

[0106] 18. The GlySer linker is (Gly4Ser) n A soluble LIFR polypeptide according to clause 17, comprising a linker.

[0107] 19. A soluble LIFR polypeptide according to any one of clauses 1 to 18, dimerized with a soluble LIFR polypeptide according to any one of clauses 1 to 18.

[0108] 20. A soluble LIFR polypeptide according to clause 19, wherein each soluble LIFR polypeptide comprises an Fc domain and dimerization is mediated through the Fc domain.

[0109] 21. A nucleic acid encoding a soluble LIFR polypeptide according to any one of clauses 1 to 18.

[0110] 22. An expression vector comprising a nucleic acid according to clause 21.

[0111] 23. A cell comprising: A soluble LIFR polypeptide according to any one of clauses 1 to 18, A nucleic acid according to clause 21, An expression vector according to clause 22, or A cell, including any combination thereof.

[0112] 24. A method for producing a soluble LIFR polypeptide according to any one of paragraphs 1 to 18, comprising: A method comprising culturing a cell comprising an expression vector according to clause 22 under conditions in which the cell produces a soluble LIFR polypeptide.

[0113] 25. The method of claim 24, further comprising introducing an expression vector into the cells prior to culturing the cells.

[0114] 26. The method of clause 24 or clause 25, further comprising purifying the LIFR polypeptide from the cells after culturing the cells.

[0115] 27. A soluble glycoprotein 130 (gp130) polypeptide comprising an amino acid sequence that is at least 70% identical to SEQ ID NO:4, wherein the gp130 polypeptide exhibits increased binding affinity for leukemia inhibitory factor (LIF) compared to a corresponding wild-type gp130 polypeptide.

[0116] 28. The soluble gp130 polypeptide according to clause 27, comprising an amino acid substitution at position K45, the position identification being relative to SEQ ID NO:4.

[0117] 29. The soluble gp130 polypeptide according to clause 28, comprising a K45E amino acid substitution.

[0118] 30. an amino acid substitution at position Y95, and an amino acid substitution at position K184; 30. The soluble gp130 polypeptide according to any one of clauses 27 to 29, wherein the positional identification is relative to SEQ ID NO:4.

[0119] 31. Y95D amino acid substitution, and A soluble gp130 polypeptide according to clause 30, comprising one or both of the following amino acid substitutions:

[0120] 32. an amino acid substitution at position F46, and an amino acid substitution at position I130, 32. The soluble gp130 polypeptide according to any one of clauses 27 to 31, wherein the positional identification is relative to SEQ ID NO:4.

[0121] 33. F46L amino acid substitution, and 33. The soluble gp130 polypeptide of clause 32, comprising one or both of the following amino acid substitutions:

[0122] 34. A soluble gp130 polypeptide according to any one of clauses 27 to 33, comprising an amino acid sequence that is at least 80% identical to SEQ ID NO:4.

[0123] 35. A soluble gp130 polypeptide according to any one of clauses 27 to 33, comprising an amino acid sequence that is at least 90% identical, or at least 95% identical, to SEQ ID NO:4.

[0124] 36. A soluble gp130 polypeptide according to any one of clauses 27 to 35, wherein the soluble gp130 polypeptide is fused to one or more heterologous polypeptides.

[0125] 37. The soluble gp130 polypeptide according to clause 36, wherein the one or more heterologous polypeptides comprise a heterologous polypeptide selected from the group consisting of an Fc domain, albumin, transferrin, XTEN, homo-amino acid polymers, proline-alanine-serine polymers, elastin-like peptides, and any combination thereof.

[0126] 38. The soluble gp130 polypeptide according to clause 37, wherein the one or more heterologous polypeptides comprises an Fc domain.

[0127] 39. A soluble gp130 polypeptide according to any one of clauses 36 to 38, wherein the one or more heterologous polypeptides comprise a soluble LIFR polypeptide according to any one of clauses 1 to 14.

[0128] 40. The soluble gp130 polypeptide according to clause 39, wherein the soluble gp130 polypeptide and the soluble LIFR polypeptide are fused via a linker.

[0129] 41. The soluble gp130 polypeptide according to clause 40, wherein the linker comprises a GlySer linker.

[0130] 42. The GlySer linker is (Gly4Ser) n A soluble gp130 polypeptide according to clause 41, comprising a linker.

[0131] 43. A soluble gp130 polypeptide according to any one of clauses 27 to 42, dimerized with a soluble gp130 polypeptide according to any one of clauses 27 to 42.

[0132] 44. A soluble gp130 polypeptide according to clause 43, wherein each soluble gp130 polypeptide comprises an Fc domain and dimerization is via the Fc domain.

[0133] 45. A nucleic acid encoding a soluble gp130 polypeptide according to any one of clauses 27 to 42.

[0134] 46. ​​An expression vector comprising a nucleic acid according to clause 45.

[0135] 47. A cell comprising: A soluble gp130 polypeptide according to any one of clauses 27 to 42, A nucleic acid according to clause 45, an expression vector as defined in clause 46, or A cell, including any combination thereof.

[0136] 48. A method for producing a soluble gp130 polypeptide according to any one of paragraphs 27 to 42, comprising: A method comprising culturing a cell comprising an expression vector according to clause 46 under conditions in which the cell produces a soluble gp130 polypeptide.

[0137] 49. The method of clause 48, further comprising introducing an expression vector into the cells prior to culturing the cells.

[0138] 50. The method of clause 48 or clause 49, further comprising purifying soluble gp130 polypeptide from the cells after culturing the cells.

[0139] 51. A heterodimeric protein comprising: A heterodimeric protein comprising a soluble LIFR polypeptide according to any one of clauses 1 to 14 dimerized with a soluble gp130 polypeptide according to any one of clauses 27 to 38.

[0140] 52. A heterodimeric protein according to clause 51, wherein the soluble LIFR polypeptide and the soluble gp130 polypeptide each contain a dimerization domain, and the soluble LIFR polypeptide and the soluble gp130 polypeptide are dimerized via the dimerization domain.

[0141] 53. The heterodimeric protein according to clause 52, wherein the dimerization domain comprises an Fc domain.

[0142] 54. A pharmaceutical composition comprising: a soluble leukemia inhibitory factor receptor (LIFR) polypeptide that binds to leukemia inhibitory factor (LIF) and comprises an amino acid sequence that is at least 70% identical to SEQ ID NO:2; and a pharma- ceutically acceptable carrier.

[0143] 55. A pharmaceutical composition comprising: a soluble glycoprotein 130 (gp130) polypeptide that binds to leukemia inhibitory factor (LIF) and comprises an amino acid sequence that is at least 70% identical to SEQ ID NO:4; and a pharma- ceutically acceptable carrier.

[0144] 56. A pharmaceutical composition comprising: a soluble leukemia inhibitory factor receptor (LIFR) polypeptide that binds to leukemia inhibitory factor (LIF) and comprises an amino acid sequence that is at least 70% identical to SEQ ID NO:2, dimerized with a soluble glycoprotein 130 (gp130) polypeptide that binds to leukemia inhibitory factor (LIF) and comprises an amino acid sequence that is at least 70% identical to SEQ ID NO:4; and a pharma- ceutically acceptable carrier.

[0145] 57. A pharmaceutical composition comprising: A soluble LIFR polypeptide according to any one of clauses 1 to 18, and a pharma- ceutically acceptable carrier.

[0146] 58. A pharmaceutical composition comprising: A soluble gp130 polypeptide according to any one of clauses 27 to 42, and a pharma- ceutically acceptable carrier.

[0147] 59. A pharmaceutical composition comprising: A heterodimeric protein according to any one of clauses 51 to 53, and a pharma- ceutically acceptable carrier.

[0148] 60. A method comprising administering to an individual in need thereof a therapeutically effective amount of a pharmaceutical composition according to any one of clauses 54 to 59.

[0149] 61. The method of clause 60, wherein the individual in need is an individual with cancer.

[0150] 62. The method according to clause 61, wherein the cancer is pancreatic cancer.

[0151] 63. A kit comprising: A pharmaceutical composition according to any one of clauses 54 to 59; and instructions for administering the pharmaceutical composition to an individual in need thereof.

[0152] 64. The kit according to clause 63, wherein the pharmaceutical composition is present in one or more unit dosage forms.

[0153] 65. The kit according to clause 63, wherein the pharmaceutical composition is present in two or more unit dosage forms.

[0154] 66. The kit according to any one of clauses 63 to 65, wherein the individual in need is an individual with cancer.

[0155] 67. The kit according to clause 66, wherein the cancer is pancreatic cancer. EXAMPLES

[0156] The following examples are offered by way of illustration and not by way of limitation.

[0157] experiment Example 1 - Recombinant soluble LIFR polypeptide In this example, LIFR variants were identified from a library of Ig-like domains of human LIFR displayed on the yeast surface and sorted for optimal binders to human LIF using FACS. After multiple rounds of sorting, variants were selected, sequenced, and characterized. The LIFR variants isolated from sorting are summarized in Figure 3.

[0158] Panel A of Figure 3 shows the consensus mutations observed in LIFR Ig-like domain variants isolated from multiple sortings. Numbering starts from the beginning of the LIFR cytokine binding motif I (CBMI) domain. Panel B of Figure 3 shows the binding scores of LIFR variants calculated from normalized total fluorescence binding values ​​at low (10 pM, 100 pM) LIF concentrations. All scores were normalized for differential expression on the yeast surface relative to wild type.

[0159] Based on the identified LIFR mutations (shown in panel A of FIG. 3), multiple combinations of possible mutant LIFR variants that were not observed in either sorting were created using site-directed mutagenesis. Panel A of FIG. 4 summarizes the variants generated using site-directed mutagenesis. Panel B of FIG. 4 shows the binding scores of such variants, calculated as described above for panel B of FIG. 3. Expression normalized to wild type (WT) is also shown. From this analysis, VPRVVAID (I217V-L218P-H240R-I257V-I206V-V262A-T271I-N277D) was identified as the optimal LIFR variant.

[0160] In Figure 5, the consensus mutations from panel A of Figure 4 are shown in a PyMOL modeled structure of human LIF (pink) bound to human LIFR (blue). Mutations are shown in red and were introduced using PyMOL. Clusters of mutations in loops 1, 2 and 3 are expanded in the inset.

[0161] Example 2 - Recombinant soluble gp130 polypeptide In this example, gp130 variants were identified from a library of the CBM domain of human gp130 displayed on the yeast surface and sorted for optimal binders to human LIF using FACS. After multiple rounds of sorting, variants were selected, sequenced, and characterized. The gp130 variants isolated from the sorting are summarized in Figure 6.

[0162] Panel A of Figure 6 shows the consensus mutations observed in gp130 CBM domain variants isolated from multiple sortings. Numbering starts from the beginning of the gp130 cytokine binding motif I (CBM) domain. Panel B of Figure 6 shows a summary of mutant gp130 variants generated using site-directed mutagenesis. Panel C of Figure 6 shows the binding scores of gp130 variants calculated as described in Panel B of Figure 3 using 100 pM and 1 nM as low LIF concentrations. Expression normalized to wild type (WT) is also shown. From this analysis, ELDME (K45E-F46L-Y95D-I130M-K184E) was identified as the optimal gp130 variant.

[0163] In Figure 7, selected consensus mutations from panel A of Figure 6 are shown in the solved structure of human LIF (blue) bound to human gp130 (pink). Mutations inserted using PyMOL are shown in cyan. Clusters of mutations in zones 1 and 2 are enlarged in the inset.

[0164] Example 3 - Binding of LIFR and gp130 variants to human LIF In this example, variants of LIFR and gp130 were displayed on the yeast surface, and binding to human LIF was measured by fluorescent antibody detection using flow cytometry.

[0165] Panel A of Figure 8 shows the binding results of wild-type LIFR and LIFR variants displayed in yeast to human LIF. Results are shown for LIFR wild-type (WT) (circles), the "PDD" variant (L218P-N42D-N277D) (squares), and the VPRVVAID variant (mutation in panel A of Figure 4) (triangles). The K of the VPRVVAID variant D was measured at 30 pM, which is a 32-fold higher affinity compared to the wild type (WT).

[0166] Panel B of Figure 8 shows the binding results of wild-type gp130 and gp130 variants displayed in yeast to human LIF. Results are shown for gp130 wild-type (WT) (circles), the "8M" variant (E4K-K5R-N14D-K45E-F46L-K83R-Y95D-N100S) (squares), and the ELDME variant (mutation in panel A of Figure 4) (triangles). The K of the ELDME variant D was measured at 5 nM, which is a 12-fold higher affinity compared to the wild type (WT).

[0167] Example 4 - Homodimeric and heterodimeric soluble LIFR and gp130 fusion polypeptides In this example, homodimeric and heterodimeric soluble LIFR and / or gp130 Fc fusion constructs were generated. Panels A and B of Figure 9 show schematics of anti-LIF monoclonal antibodies G1 and L1, which target the gp130-binding and LIFR-binding faces of LIF, respectively. These antibodies serve as efficacy benchmarks.

[0168] Schematically depicted in Figure 9, panel C is a gp130 cytokine binding motif (CBM) variant (ELDME) Fc fusion homodimer, where dimerization is via the Fc domain. This construct may be referred to as "gp130 ELDME Fc."

[0169] Panel D of Figure 9 shows a schematic of a LIFR cytokine binding motif 1-Ig-like-cytokine binding motif 2 (CBMI-Ig-like-CBMII) variant (VPRVVAID) Fc fusion homodimer, where dimerization is via the Fc domain. This construct may be referred to as "LIFR VPRVVAID Fc."

[0170] Schematically depicted in Figure 9, panel E is a homodimer in which each monomer contains the LIFR CBMI-Ig-like-CBMII VPRVVAID variant fused to the gp130 CBM ELDME variant via a 5x Gly4Ser linker. The Fc domain is C-terminal to the gp130 portion, and dimerization is achieved via the Fc domain. This construct may be referred to as "LIFR-gp130 VE fusion to Fc."

[0171] FIG. 9, panel F, shows a schematic representation of a heterodimer comprising the gp130 ELDME Fc monomer shown in panel C and the LIFR VPRVVAID Fc monomer shown in panel D, dimerized via the Fc domain.

[0172] Each of the constructs shown diagrammatically in Figure 9, panels C-F, was successfully expressed and purified.

[0173] Binding of purified LIF inhibitors to soluble LIF was tested using KinExA. Figure 10 shows binding results for (1) homodimers with WT LIFR CBMI-Ig-like-CBMII Fc fusion as each monomer, (2) homodimers with LIFR VPRVVAID Fc as each monomer, and (3) homodimers with LIFR-gp130 VE fusion Fc as each monomer. D Values ​​were calculated from KinExA software and fitted curves are shown. LIFR-VPRVVAID-Fc has an affinity of 23 pM for human LIF, a 43-fold improvement compared to LIFR-WT-Fc.

[0174] Example 5 - Multiple LIF binding assay A binding assay was performed as shown diagrammatically in panel A of FIG. 11 to determine whether the receptor decoy bound to LIF can also engage another LIF molecule. The goal was to show whether an inhibitor that is homodimeric as an Fc fusion can bind to LIF simultaneously at each arm of the dimer. With this assay, LIF is displayed on the yeast surface. The Fc fusion inhibitor (LIFR-VPRVVAID-Fc shown) is introduced at saturating concentrations and allowed to bind to the displayed ligand, and the excess is washed away. Soluble LIF-His is then co-cultured with the Fc fusion-bound yeast. LIF binding is detected via the His-tag domain of LIF-His, which should only be present if multiple LIF binding to the Fc fusion occurs, with the homodimer acting as a "bridge".

[0175] The results of the multiple LIF binding assay are shown in panel B of FIG. 11. LIF was displayed on yeast, and Fc fusion inhibitors were used as a binding bridge between displayed LIF and soluble LIF. Fluorescence emission from anti-His6 tag fluorescent antibody in each condition was normalized to the control without added LIF-His. Fc fusion binding to displayed LIF was also confirmed using anti-Fc tag fluorescent antibody (data shown in panel B of FIG. 12). The multiple LIF binding results are shown for LIFR-WT-Fc, LIFR-VPRVVAID-Fc, LIFR-gp130 fusion-Fc, and anti-LIF mAb L1.

[0176] These results determine that all four homodimers tested can bind multiple LIF molecules. Recombinant LIFR-Fc shows improved multiple LIF binding compared to LIFR-WT-Fc, likely due to improved affinity to LIF and slower off-rate (described in Example 6). LIFR-gp130 fusion-Fc shows the greatest multiple LIF binding capacity, likely due to the presence of four LIF binding domains. Both recombinant Fc fusions show greater multiple LIF binding, potentially due to higher affinity, when compared to anti-LIF mAb, L1. Overall, these results imply that as Fc fusions, inhibitors can bind to LIF with a 2:1 LIF:inhibitor stoichiometry, providing the potential for even greater therapeutic benefit through multiple LIF binding and sequestration.

[0177] Example 6 - Competitive LIF binding assay A binding assay was performed as shown diagrammatically in panel A of FIG. 12 to determine how much of the LIF-bound receptor decoy remains bound to LIF in the presence of excess soluble LIF competitor. The goal was to determine whether the recombinant receptor causes a slower off-rate, as indicated by improved resistance to competition by excess competitor. With this assay, LIF is displayed on the yeast surface. An Fc fusion inhibitor (LIFR-VPRVVAID-Fc shown) is introduced at saturating concentrations and allowed to bind to the displayed ligand, and the excess is washed away. Soluble LIF-His is then co-cultured with Fc fusion-bound yeast. Fc fusion binding is detected via the Fc domain of the inhibitor, which can be competed off by high concentrations of soluble LIF-His and dissociated from the yeast-displayed LIF.

[0178] The results of the competitive LIF binding assay are shown in Figure 12, panel B. LIF was displayed on yeast and LIFR-WT-Fc, LIFR-VPRVVAID-Fc, LIFR-gp130 fusion-Fc, or the anti-LIF mAb L1 was added as a binding partner. Excess inhibitor was washed away and soluble LIF was added as a competitor for 24 hours. Fluorescence emission from the anti-Fc fluorescent antibody in each condition was normalized to a control in which excess inhibitor was not removed and soluble LIF was not added.

[0179] From these results, it is determined that recombinant LIFR-Fc and LIFR-gp130 fusion-Fc have dramatically improved off-rates when compared to LIFR-WT-Fc. This is most pronounced in the presence of high levels (100 nM) of LIF-His competitor, where the recombinant receptor remains more than 50% bound, while LIFR-WT-Fc is almost completely competed away from yeast-displayed LIF. The relative amount of Fc fusion that remains bound is comparable to the anti-LIF mAb, L1. The improved off-rates exhibited by the recombinant Fc fusions likely partially explain the improved affinity, which should translate into greater therapeutic efficacy.

[0180] Example 7 - Simultaneous receptor binding assay A binding assay was performed as shown diagrammatically in panel A of FIG. 13 to determine whether the receptor decoy bound to LIF can also simultaneously engage with gp130 or LIFR. The goal was to show whether the inhibitor competes with LIFR, gp130, or both in binding to LIF. With this assay, gp130 (shown) or LIFR is displayed on the yeast surface. LIF is introduced at saturating concentrations and allowed to bind to the displayed receptor, and the excess is washed away. The inhibitor (LIFR-VPRVVAID-Fc shown) is then co-cultured with the LIF-bound yeast. Binding is detected via the Fc domain of the inhibitor, which should only be present if simultaneous receptor binding occurs using LIF as a "bridge". If inhibitor binding is not detected, it is determined that the displayed receptor is in competition with the co-incubated inhibitor, thus preventing the inhibitor from binding to LIF.

[0181] The results of the simultaneous binding assay are shown in panel B of FIG. 13. Either LIFR or gp130 was displayed on yeast, and human LIF was used as a binding bridge. Fluorescence emission is the readout of an anti-Fc fluorescent antibody, normalized to a control with no added LIF. LIF binding to the displayed receptor was also confirmed using an anti-His6 tag fluorescent antibody (data not shown). Results of simultaneous binding of LIFR-VPRVVAID-Fc, gp130-ELDME-Fc, LIFR-gp130 heterodimer Fc, LIFR-gp130 homodimer fusion-Fc, anti-LIF mAb L1, and anti-LIF mAb G1 are shown.

[0182] From these results, it is determined that LIFR-Fc can bind to the LIF-gp130 complex (and to a much lesser extent, and somewhat surprisingly, to the LIF-LIFR complex), while gp130-Fc can only bind to the LIF-LIFR complex. This means that LIFR-Fc effectively blocks LIFR from binding to LIF, while gp130-Fc blocks gp130 from binding to LIF. Polypeptides with both receptors (heterodimeric Fc and fusion Fc) show simultaneous binding to both presented receptors to a relatively equal extent. Anti-LIF monoclonal antibodies (mAbs) L1 and G1 can only simultaneously bind to one presented receptor-LIF complex each, i.e., gp130-LIF or LIFR-LIF, respectively. This means that L1 competes with LIFR (no inhibitor binding is observed when LIFR is presented), whereas G1 competes with gp130 (no inhibitor binding is observed when gp130 is presented). Thus, in terms of inhibitory mechanism, L1 is comparable to LIFR-Fc, whereas G1 is comparable to gp130-Fc. In all cases, no binding is observed in the absence of LIF, indicating that LIF is required for simultaneous binding.

[0183] Example 8 - Competitive Binding Assay A competitive binding assay was performed as shown diagrammatically in panel A of FIG. 14. According to this assay, wild-type gp130 or LIFR (as shown) is displayed on the yeast surface. Human LIF-His is introduced at saturating concentrations. An inhibitor (LIFR-VPRVVAID-Fc as shown) is then co-cultured in excess with the LIF-bound yeast. LIF binding is detected via the His6-tag on LIF. The less LIF that remains bound after inhibitor incubation, the better the inhibitor has been able to compete LIF away from the WT receptor.

[0184] The results of the competitive binding assay are shown in Figure 14, panel B. Either wild-type LIFR or gp130 was displayed on yeast and saturated with human LIF-His. The bound ratio is the fluorescence emission detected from LIF-His normalized to no inhibitor added. Competitive binding of LIFR-WT-Fc, gp130-ELDME-Fc (recombinant), LIFR-VPRVVAID-Fc (recombinant), LIFR-gp130 fusion-Fc (recombinant), LIFR-gp130 heterodimer Fc (recombinant), anti-LIF mAb L1, and anti-LIF mAb G1 is shown.

[0185] From these results, it is determined that wild-type LIFR-Fc competes to dissociate LIF from wild-type LIFR and, unexpectedly, from gp130. Recombinant LIFR-Fc is an improvement over wild-type LIFR-Fc in this respect, and can strongly compete to dissociate LIF from both LIFR and gp130. Recombinant gp130-Fc competes well with gp130 to dissociate LIF, but as expected, has no effect on the ability of LIFR to bind to LIF. Fusions of LIFR and gp130, both as homodimers and heterodimers, show a strong ability to compete to dissociate LIF from both LIFR and gp130, as expected by having both recombinant receptors in the same inhibitor. The anti-LIF monoclonal antibodies L1 and G1 effectively compete with and sequester LIF from only one receptor, LIFR and gp130, respectively, but actually enhance LIF binding to the opposite receptors, gp130 and LIFR, respectively.

[0186] Example 9 - Blockade of downstream LIF signaling in HeLa luciferase reporter cells LIF binds to LIFR and gp130, causing the heterodimerization of LIFR and gp130. Dimerization recruits JAK and phosphorylates STAT3. This leads to STAT3 dimerization, entry into the nucleus, and activation of transcriptional programming via STAT3 response element. Cell lines can be modified to contain the gene for luciferase preceded by STAT3 response element, so that activation of pSTAT3 produces luciferase. In this situation, luciferase activity determined using standard luciferase assay with luciferin can be directly correlated with LIF signaling in cells. Panel A of Figure 15 shows a schematic of this LIF reporter cell line in HeLa cells.

[0187] Shown in panel B of FIG. 15 are results from a luciferase assay, where HeLa reporter cells were exposed to 0.5 nM LIF and different concentrations of LIFR-VPRVVAID-Fc, LIFR-VPRVVAID-gp130-ELDME Fc, and LIFR-WT-Fc. Cells were incubated for 5 hours before being lysed and luciferase assayed. Results are normalized to no inhibitor added. Panel C of FIG. 15 shows results from a delayed inhibitor addition assay. According to this assay, 0.5 nM LIF is added to HeLa reporter cells for 1.5 hours, and then either LIFR-VPRVVAID-Fc, LIFR-WT-Fc, or LIFR-VPRVVAID-gp130-ELDME Fc is added directly to the wells at 5 nM, 25 nM, or 50 nM. Luciferase levels are measured 20 hours after LIF addition. Results are baseline subtracted and normalized to no inhibitor added. Panel D of Figure 15 shows the IC for LIFR-VPRVVAID-Fc. 50Figure 15 shows LIF-derived luciferase inhibition over a wide range of inhibitor concentrations to determine the inhibition of LIF relative to LIFR-WT-Fc. After recombination, a 53-fold shift in improved inhibition is observed. Figure 15, panel E, takes advantage of the ability of HeLa reporter cells to respond to multiple IL-6 family member cytokines, including oncostatin-M (OSM), a close relative of LIF. Cells were incubated with 0.5 nM LIF or OSM and either 1 μM LIFR-VPRVVAID-Fc or LIFR-WT-Fc for 5 hours and luciferase levels were measured.

[0188] Taken together, these results indicate that LIFR-VPRVVAID-Fc and LIFR-VPRVVAID-gp130-ELDME Fc, even at low concentrations, can potently reduce LIF-mediated downstream signaling and significantly block LIF signaling when added after LIF is already present in the medium, which is a promising sign for therapeutics. When compared to LIFR-WT-Fc, both recombinant inhibitors showed much better inhibition, with a significantly lower IC by LIFR-VPRVVAID-Fc compared to LIFR-WT-Fc. 50 There was a 53-fold improvement in the efficacy of LIF over WT and recombinant LIFR-Fc. Both WT and recombinant LIFR-Fc show a high degree of specificity for LIF and show no reduction in OSM-derived luciferase signal even at high receptor concentrations, despite the fact that OSM can bind to LIFR. The fact that the recombinant inhibitor is more selective for LIF than the WT due to its high affinity indicates that there is likely no off-target toxicity associated with this recombinant trap as a therapeutic.

[0189] Example 10 - Ablation of LIF signaling in pancreatic cancer cells LIF binds to LIFR and gp130, causing heterodimerization of LIFR and gp130. Dimerization recruits JAKs, which phosphorylate STAT3 on tyrosine 705. This leads to STAT3 dimerization, nuclear entry, and activation of transcriptional programming. Thus, pSTAT3-Y705 is a readout of LIF signaling. Panel A of FIG. 16 shows a schematic of LIF signaling.

[0190] Panel B of FIG. 16 shows Western blot results of lysates from PANC1 (human pancreatic cancer cell line) exposed to 135 pM human LIF and different concentrations of LIFR-VPRVVAID-Fc ("LIFR Fc recombinant"), LIFR-WT-Fc ("LIFR Fc WT"), LIFR-VPRVVAID-gp130-ELDME Fc ("fusion Fc recombinant"), and L1 anti-LIF mAb ("anti-LIF mAb"). Cells were incubated at 37° C. for 20 min and then lysed in the presence of protease and phosphatase inhibitors. Protein concentrations were normalized and run on gels by SDS-PAGE. Western blots were stained for phospho-STAT3 (Y705), STAT3 (total), and β-tubulin. Panel C of FIG. 16 shows quantification of pSTAT3 signal normalized to tubulin signal.

[0191] These results show that LIFR-VPRVVAID-Fc and LIFR-VPRVVAID-gp130-ELDME Fc can reduce LIF-mediated pSTAT3 levels in cancer cells even when incubated at only approximately 3-fold excess, and can completely ablate LIF signaling when incubated at higher therapeutically relevant excesses. The degree of inhibition is improved over the anti-LIF mAb, L1, as shown by quantification (panel C). LIFR-WT-Fc was much less effective at blocking LIF-derived signaling, demonstrating the advantage gained by affinity engineering. Potent signal inhibition was also observed in KP4 human pancreatic cancer cells (not shown).

[0192] Thus, the above merely describes the principles of the disclosure. It will be appreciated that those skilled in the art will be able to devise various configurations that embody the principles of the invention and are within its spirit and scope, although not explicitly described or illustrated herein. Furthermore, all examples and conditional language recited herein are intended primarily to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to advance the art, and should not be construed as limitations to such specifically recited examples and conditions. Furthermore, all descriptions herein reciting the principles, aspects, and embodiments of the invention, as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. In addition, such equivalents are intended to include both currently known equivalents and equivalents developed in the future, i.e., any developed elements that perform the same function, regardless of structure. Thus, the scope of the present invention is not intended to be limited to the exemplary embodiments shown and described herein.

Claims

1. A soluble leukemia inhibitory factor receptor (LIFR) polypeptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:2, and which has the following amino acid substitutions: (a) L218P, V262A, T273I, and N277D; or (b) L218P, N242D, I257V, and N277D Including, A soluble LIFR polypeptide, wherein the positional identification is for SEQ ID NO:2, and wherein said LIFR polypeptide exhibits increased binding affinity for leukemia inhibitory factor (LIF) compared to a corresponding wild-type LIFR polypeptide.

2. A soluble LIFR polypeptide as described in claim 1, comprising an L218P amino acid substitution, a V262A amino acid substitution, a T273I amino acid substitution, an N277D amino acid substitution, an H240R amino acid substitution, and an I257V amino acid substitution.

3. 3. The soluble LIFR polypeptide of claim 1 or 2, comprising an I217V amino acid substitution, an N242D amino acid substitution, an I260V amino acid substitution, a V262A amino acid substitution, or any combination thereof.

4. The soluble LIFR polypeptide of claim 2, further comprising an I217V amino acid substitution, an N242D amino acid substitution, and an I260V amino acid substitution.

5. The soluble LIFR polypeptide of any one of claims 1 to 4, comprising an amino acid sequence which is at least 95% identical to SEQ ID NO:

2.

6. The soluble LIFR polypeptide of any one of claims 1 to 5, wherein the soluble LIFR polypeptide is fused to one or more heterologous polypeptides.

7. 7. The soluble LIFR polypeptide of claim 6, wherein the one or more heterologous polypeptides comprise a heterologous polypeptide selected from the group consisting of an Fc domain, albumin, transferrin, XTEN, a homo-amino acid polymer, a proline-alanine-serine polymer, an elastin-like peptide, and any combination thereof.

8. The soluble LIFR polypeptide of claim 7 , wherein the one or more heterologous polypeptides comprises an Fc domain.

9. The soluble LIFR polypeptide of any one of claims 6 to 8, wherein the one or more heterologous polypeptides comprise a soluble glycoprotein 130 (gp130) polypeptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:4, the gp130 polypeptide exhibiting increased binding affinity for leukemia inhibitory factor (LIF) compared to a corresponding wild-type gp130 polypeptide, and the soluble LIFR polypeptide and the soluble gp130 polypeptide are fused via a linker.

10. A soluble LIFR polypeptide according to any one of claims 1 to 9, which is dimerized with a soluble LIFR polypeptide according to any one of claims 1 to 9 of the second claim.

11. The soluble LIFR polypeptide of claim 10, wherein each soluble LIFR polypeptide is fused to an Fc domain and dimerization is mediated through the Fc domain.

12. A nucleic acid encoding a soluble LIFR polypeptide according to any one of claims 1 to 9.

13. A cell comprising the nucleic acid of claim 12.

14. A soluble LIFR polypeptide according to any one of claims 1 to 9, and a pharma- ceutical composition comprising a pharma- ceutical acceptable carrier.

15. 15. The pharmaceutical composition of claim 14 for use in a method comprising administering a therapeutically effective amount of said pharmaceutical composition to an individual in need thereof.

16. The pharmaceutical composition of claim 15, wherein the individual in need thereof is an individual with cancer.

17. The pharmaceutical composition of claim 16, wherein the cancer is pancreatic cancer.

18. A kit comprising the pharmaceutical composition of any one of claims 14 to 17 and instructions for administering said pharmaceutical composition to an individual in need thereof.

19. 20. The kit of claim 18, wherein the pharmaceutical composition is present in two or more unit dosage forms.

Citation Information

Patent Citations

  • Leukemia inhibitory factor receptors

    JP1994504438A

  • Receptor for oncostatin m and leukemia inhibitory factor

    JP1995501941A